NCT05237752View on ClinicalTrials.gov

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

April 27, 2022

Primary Completion Date

December 19, 2023

Study Completion Date

March 11, 2024

Conditions
Osteoarthritis, Knee
Interventions
DRUG

LG00034053

a pan-caspase inhibitor, as a therapeutic agent of osteoarthritis

Trial Locations (2)

Unknown

Emeritus Research, Camberwell

The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT05237752 - A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA | Biotech Hunter | Biotech Hunter